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ABSTRACT
Background Low-tar cigarette smoking is gaining
popularity in China. The China National Tobacco
Corporation (CNTC) promotes low-tar cigarettes as safer
than regular cigarettes.
Methods A total of 543 male smokers smoking
cigarettes with different tar yields (15 mg, regular
cigarettes, 10e13 mg low-tar cigarettes and <10 mg
low-tar cigarettes) were recruited in Shanghai, China,
who then completed a questionnaire on smoking
behaviour and provided a urine sample for analysis of the
nicotine metabolites cotinine and trans-39-
hydroxycotinine. A total of 177 urine samples were
selected at random for the analysis of the carcinogens
polycyclic aromatic hydrocarbon metabolites (PAHs)
(1-hydroxypyrene, naphthols, hydroxyﬂuorenes and
hydroxyphenanthrenes) and the tobacco speciﬁc
nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-
butanone (NNK) metabolites, 4-(methylnitrosamino)-1-
(3-pyridyl)-butanol (NNAL) and NNAL-glucuronide.
Values were normalised by creatinine to correct for
possible distortions introduced by dilution or
concentration of the urine.
Results Smokers of low-tar cigarettes smoked fewer
cigarettes per day (p¼0.001) compared to smokers of
regular cigarettes. Despite this lower reported
consumption, levels of cotinine, trans-39-hydroxycotinine
and PAHs in urine of people smoking low-tar cigarettes
were not correlated with nominal tar delivery of the
cigarettes they smoked. Urine concentrations of NNAL
were higher in smokers of lower tar than higher tar
cigarettes.
Conclusions Chinese low-tar cigarettes do not deliver
lower doses of nicotine and carcinogens than regular
cigarettes, therefore it is unlikely that there would be any
reduction in harm. CNTC’s promotion of low-tar
cigarettes as ‘less harmful’ is a violation of the World
Health Organization Framework Convention on Tobacco
Control, which China ratiﬁed in 2005.
INTRODUCTION
Beginning in the 1950s, tobacco companies
embarked on an effort to design cigarettes with
lower yields of carcinogenic tar, with the hope that
doing so would lead to less dangerous cigarettes.
1e3
While this effort failed to produce less dangerous
cigarettes, the companies discovered that cigarettes
with lower tar yields (measured by a smoking
machine) would appeal to health-concerned
smokers even though the actual delivery of nicotine
and carcinogens to people was not affected by the
design changes to cigarettes.
245Low-yield ciga-
rettes were designed to burn faster and to have
greater ventilation, (adding small ventilation holes
to the ﬁlters that diluted the smoke delivered to
the smoking machines). However, smokers easily
compensated for these design changes by pufﬁng
more frequently and more intensively and blocking
ventilation holes so as to maintain desired levels
of nicotine in the body.
2
Legal concerns forced the tobacco companies to
be circumspect in making explicit health claims for
so-called ‘light’ and ‘mild’ low (machine) delivery
cigarettes, but the popularity of low-tar cigarette
smoking increased dramatically.
2 The fact that the
tobacco companies extensively researched the
compensatory behaviours of low-tar cigarette
smokers and engineered cigarette design to obtain
low readings of nicotine and tar from smoking test
machines while maintaining intake by smokers
16 e8
was a central element of Federal Judge Gladys
Kessler’s 2006 ruling
9 that US tobacco companies
violated the Racketeer Inﬂuenced and Corrupt
Organizations (RICO) Act by systematically
defrauding the public. As part of her remedy (under
appeal as of April 2010), she ordered the companies
to stop using the terms ‘light’ and ‘mild’.
91 0For the
same reasons, the World Health Organization
Framework Convention on Tobacco Control (WHO
FCTC), the global public health ratiﬁed by 168
countries (as of April 2010), requires parties to pass
laws banning the use of terms ‘light’ and ‘mild.
11
The China National Tobacco Corporation
(CNTC), which is part of the government as
the State Tobacco Monopoly Agency (STMA), is
the largest cigarette producer in the world and the
dominant company in the Chinese market. CNTC
initiated a nationwide effort in the mid 1980s to
lower the machine-measured tar level of cigarettes
produced in China.
12 Because of CNTC’s tar
reduction effort, the average machine-measured tar
delivery of cigarettes sold in China dropped from
26.1 mg/cigarette in 1985 to 20 mg/cigarette in
1991 to 12.8 mg/cigarette in 2008 (ﬁgure 1). In
2004, CNTC set 15 mg as the maximum allowed
limit of tar delivery for cigarettes sold in China.
13
CNTC’s tar reduction campaign has been accom-
panied with increasing popularity of lower-yield
cigarettes among Chinese smokers. A 2007 survey
found that nearly 20% of the cigarettes sold in
China had tar levels below 12 mg,
14 up from 5.6%
in 2002.
12 In some areas such as Beijing, Shanghai,
Dalian and Fujian, more than 2% of the cigarettes
sold had a tar level at or below 8 mg.
14 In 2006
CNTC stated that it put ‘developing less harmful
cigarettes’ (including low-tar cigarettes) as one of
the main focuses of its ‘Research and Development
Plan for 2006e2020’.
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Research paperWhile the issue of smoking low-yield cigarettes has been
thoroughly researched and has received considerable press
attention in Western countries, this is not the case in China. Few
published studies have examined the validity of the health
claims related to Chinese low-tar cigarettes.
16 17 The Chinese
low-tar cigarettes are promoted by CNTC as ‘less harmful’
alternatives to regular cigarettes much more explicitly than they
have been in the US and other Western countries (ﬁgure 2). A
2007 survey in eight major metropolitan areas in China found
that 71% of respondents believed that ‘Low-tar cigarettes are
less harmful to health’.
14 As cigarettes are produced differently
in different countries, it is important to examine the issue of
low-tar cigarettes in China.
The present study tests the statement that Chinese low-tar
cigarettes are less harmful than regular cigarettes by comparing
the presence of nicotine metabolites and tobacco smoke carcino-
gens in urine from smokersoflow-tarand regular cigarettes. As in
theWesternworld,wefoundthatpeoplesmokingcigaretteswith
lower machine-measured tar yields were not exposed to less
nicotine or carcinogens than those smoking regular cigarettes.
METHODS
Sampling protocol
Data for this study were collected in Shanghai, China from
January to April 2008. All participants were Chinese smokers
smoking Chinese brand cigarettes. A total of 543 participants
were recruited at 4 driver physical examination centres in
Shanghai, where drivers with local licenses are required to take
physical exams every 1e6 years (depending on the type of the
license). Participants were asked to show the interviewer the
packaging of the cigarettes they smoked the most, and the tar
reading on the package was recorded. Several inclusion and
exclusion criteria were applied: (1) female smokers were
excluded because few women smoke in China; (2) participants
had to be between the ages of 18 and 65, with no diagnosis of
cancer, heart disease or major respiratory diseases; (3) partici-
pants had to smoke on average at least ﬁve cigarettes per day;
and (4) participants had to have been smoking their current
brand for at least 3 months. Since brand mixing is common
among smokers in China, a ‘main brand’ approach was used to
determine the cigarette tar level of each participant. For each
eligible participant, a consent form was signed and a question-
naire survey was administered. At the end of the survey, a 25 ml
urine sample was collected from the participant.
The protocol was approved by the University of California
San Francisco Committee on Human Research and the Shanghai
Center for Disease Control and Prevention Committee on
Human Subjects.
Analysis of tobacco smoke compounds in smokers’ urine
The urine samples were frozen and shipped to San Francisco
General Hospital for analysis at the Tobacco Biomarker Core
Facility of the UCSF Helen Diller Family Comprehensive Cancer
Center. Cotinine and trans-39-hydroxycotinine, both major
metabolites of nicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-
butanol (NNAL) and NNAL-glucuronide, metabolites of nitro-
samine 4-(methylnitrosamino)-1-(3-pyridyl)-butanol (NNK), a
tobacco speciﬁc nitrosamine and one of the most potent
carcinogens in tobacco smoke,
18 and metabolites of polycyclic
aromatic hydrocarbons (PAHs), which represent a class of com-
bustion products that include a number of carcinogens, were
measured. Cotinine and trans-39-hydroxycotinine were mea-
sured using liquid chromatography by methods described pre-
viously.
19 NNAL and NNAL-glucuronide were assayed by liquid
chromatographyemass spectrometry and are reported as total
NNAL.
20 Metabolites of the PAHs included 1-hydroxypyrene,
naphthols, hydroxyﬂuorenes and hydroxyphenanthrenes, and
Figure 1 Average machine-measured
tar content of cigarettes in the Chinese
market has declined over 25 years
(adapted from Lei et al
12).
Figure 2 A 2007 magazine advertisement of one of the leading low-tar
cigarette brands in China ‘Zhongnanhai’. The print at the bottom of the
ﬁgure reads: ‘A little lower means more loving care! Low-harm
cigarettes give you more loving care! Cigarettes contain conﬂicting
elements of pleasure and harm. Zhongnanhai has always focused on
research and development of low-harm cigarette technology. Every
product fuses the world’s most advanced low-harm cigarette tech-
nology, offering a guarantee of health for your smoking life’. (Photo
courtesy of Susan Lawrence of the Tobacco Free Kids China Ofﬁce.)
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and are reported as total PAHs.
20 21 Concentrations of cotinine,
trans-39-hydroxycotinine, total PAHs and total NNALs were
normalised by urine creatinine to correct for variations due to
dilution or concentration of urine. Per cigarette levels were esti-
mated by dividing creatinine-normalised cotinine, trans-39-hy-
droxycotinine, total PAHs and total NNAL concentrations by the
number of cigarettes the participant reported smoking per day.
All of the 543 participants with urine samples were tested for
cotinine and trans-39-hydroxycotinine levels. Because of cost
considerations, a random sample of 180 was selected for the
analysis of total PAHs and total NNAL. The subsample was not
different from the larger sample in cotinine, trans-39-hydrox-
ycotinine, cigarettes smoked per day, or demographic indices. In
all, 22 participants were excluded from the study as a result of
low cotinine levels typical of non-smokers (<50 mg/litre) and
another 5 participants were excluded because of incomplete
questionnaires. This process left a sample of 516 participants for
the laboratory analysis of cotinine and trans-39-hydroxycotinine
and a sample of 177 participants for the analysis of total PAHs
and total NNAL. There were no statistically signiﬁcant differ-
ences in cotinine, trans-39-hydroxycotinine, cigarettes per day or
demographic indices between participants in the PAH and
NNAL carcinogen sample and the full sample (data not shown).
Table 1 Metabolites of nicotine and carcinogen levels by nominal tar ratings
Nominal tar rating (per
cigarette)* 15 mg 13 mg 12 mg 10 mg 8 mg rS
p
Valuey
Demographics
Sample size 175 43 74 51 165
Age in years, mean (SD) 44.5 (8.9) 46.9 (8.1) 42.2 (8.1) 43.3 (10.5) 43.3 (9.5) 0.075 0.089
Education, N (%)  0.063 0.154
Junior high school and
below
52 (30%) 26 (60%) 19 (26%) 19 (37%) 42 (25%)
Secondary technical
school
93 (53%) 13 (30%) 37 (50%) 27 (53%) 86 (52%)
Junior college 21 (12%) 4 (9%) 11 (15%) 4 (8%) 27 (16%)
College and above 9 (5%) 0 (0%) 7 (9%) 1 (2%) 10 (6%)
Employment status, N (%) 0.022 0.617
Employed 164 (94%) 38 (88%) 69 (93%) 45 (88%) 152 (92%)
Unemployed 11 (6%) 5 (12%) 5 (7%) 6 (12%) 13 (8%)
Monthly income, N (%) 0.039 0.373
<500 yuan 7 (4%) 5 (12%) 4 (5%) 5 (10%) 8 (5%)
500e999 yuan 1 (1%) 3 (7%) 0 (0%) 1 (2%) 6 (4%)
1000e1999 yuan 30 (17%) 18 (42%) 9 (12%) 5 (10%) 32 (19%)
2000e4999 yuan 107 (61%) 16 (37%) 47 (64%) 32 (63%) 100 (61%)
$5000 yuan 30 (17%) 1 (2%) 14 (19%) 8 (16%) 19 (12%)
Change in daily consumption after switching from regular cigarettes
(15 mg) to cigarettes with lower disclosed tar ratings
 0.052 0.398
Decreased daily
consumption
11% 14% 14% 13%
No change in daily
consumption
56% 64% 57% 52%
Increased daily
consumption
33% 21% 28% 34%
Cigarettes/dayz 20 (10e20) 18 (10e20) 11 (10e20) 20 (10e20) 15 (10e20) 0.152 0.001
Nicotine metabolites*
Cotinine (mg/mg
creatinine)
16.1 (8.9e27.0) 14.4 (7.2e32.7) 12.8 (7.1e20.4) 14.9 (7.6e28.0) 16.1 (8.2e25.4) 0.012 0.654
Cotinine/cigarette
(mg/mg creatinine)
0.84 (0.56e1.50) 0.93 (0.56e2.12) 0.91 (0.60e1.66) 0.71 (0.42e1.75) 1.00 (0.56e1.85)  0.068 0.123
Trans-39-hydroxycotinine
(mg/mg creatinine)
33.3 (16.4e63.4) 37.2 (19.3e74.4) 25.8 (10.9e48.0) 31.9 (19.2e64.9) 38.0 (16.9e62.6) 0.001 0.974
Trans-39-
hydroxycotinine/cigarette
(mg/mg creatinine)
2.02 (0.92e3.36) 1.99 (1.00e4.51) 2.04 (0.76e4.14) 2.02 (1.06e3.51) 2.39 (1.26e4.11)  0.071 0.109
Carcinogens*
Sample size 60 14 28 18 56
Total PAHs (pmol/mg
creatinine)
153 (95e195) 159 (113e206) 142 (94e177) 152 (105e224) 121 (88e166) 0.125 0.099
Total PAHs/cigarette
(pmol/mg creatinine)
8.46 (5.31e13.22) 8.33 (6.99e16.08) 9.66 (6.99e14.30) 10.4 (5.36e16.42) 6.72 (4.40e10.98) 0.109 0.149
NNAL (pmol/mg
creatinine)
0.22 (0.16e0.37) 0.35 (0.22e0.41) 0.26 (0.20e0.36) 0.33 (0.22e0.45) 0.292 (0.190e0.479)  0.148 0.050
NNAL/cigarette (pmol/
mg creatinine)
0.0160 (0.00918e0.0220) 0.0217 (0.0118e0.0402) 0.0212 (0.0121e0.0406) 0.0198 (0.0146e0.0352) 0.0200 (0.0111e0.0324)  0.146 0.053
*The tabulated results in this table do not include three participants who smoked 5 mg tar cigarettes, one who smoked 9 mg cigarettes, three who smoked 11 mg cigarettes and one who
smoked 14 mg tar cigarettes because of small numbers. These data are, however, included in the calculation of the Spearman rank order correlations and associated p values.
yThese are bivariate p values; there was no adjustment for any demographic variables.
zMedian (IQR).
NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-butanol; PAH, polycyclic aromatic hydrocarbon metabolites.
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The relationships between tar ratings and all variables were
tested using Spearman rank order correlations with demographic
variables recoded as ordinal variables. Performing the analysis
using a non-parametric Spearman rank order correlation based
on actual tar levels is a more sensitive method than treating the
data as ‘groups’ in an analysis of variance for two reasons: ﬁrst,
treating the samples as groups disregards the fact that tar is
measured on an interval scale, not a categorical scale; not taking
advantage of this fact would reduce the power of the analysis.
Second, grouping the data would increase the within-group
variance and reduce the power of the analysis.
Role of the funding sources
The funding sources played no role in study design, the collec-
tion, analysis, interpretation of the data, the writing of the
report, or in the decision to submit the paper for publication.
RESULTS
Demographic information for the participants is presented in
table 1. There was no signiﬁcant relationship between any of the
demographic variables and the tar levels of the cigarettes they
smoked. Reported number of cigarettes per day was positively
correlated with tar level (p<0.001); smokers of lower tar ciga-
rettes tended to consume fewer cigarettes per day than smokers
of higher tar cigarettes.
Cigarette switching
Among 353 smokers of low-tar cigarettes (<14 mg), 276 had
switched to their current brand from a previous brand with
a median of 5 years ago (IQR: 2e7 years). In all, 230 switched
from a higher yield brand to a lower yield brand, including 120
who switched from regular cigarettes. The most often cited
reason for switching to brands with lower tar yields was ‘better
taste’ (50%). Price was also one of the main reasons for
switching to brands with lower tar yields (21%). Although
generally low-tar cigarettes are more expensive than regular
cigarettes in China, we observed two opposing concerns about
price as reason for switching: some smokers switched because
the current brand was more affordable (5%), while others
switched because the current brand was more expensive and
‘good for face’ when offering cigarettes to others (16%), which is
a common social etiquette in China. Health concern was
reported as the third most popular reason for switching to
lower-yield cigarettes (15%).
Urine levels of nicotine metabolites, total PAHs and total NNAL
There was no signiﬁcant relationship between nominal tar
rating and levels of the nicotine metabolites cotinine and trans-
39-hydroxycotinine in the smokers’ urine (ﬁgure 3 and table 1) or
levels per cigarette smoked (table 1). Total PAHs followed the
same pattern as cotinine and trans-39-hydroxycotinine, and
showed no signiﬁcant difference across different nominal tar
ratings (ﬁgure 4 and table 1). A signiﬁcant inverse (p¼0.050)
relationship was detected between total NNAL in the smokers’
urine and tar rating of the cigarettes (ﬁgure 4 and table 1), with
the relationship remaining borderline signiﬁcant (p¼0.053) after
controlling for daily consumption of cigarettes (table 1).
DISCUSSION
The results of the current study do not support the Chinese
tobacco industry’s claims (ﬁgure 2) that low-tar cigarettes are
safer products. As in the US,
2 we did not ﬁnd that smoking
cigarettes with lower machine yields of tar was associated with
lower levels of nicotine metabolites or the carcinogen biomarker
total PAHs in smokers’ urine. In contrast to what might be
expected (particularly since smokers on lower tar cigarettes
reported lower levels of consumption), levels of the carcinogen
NNAL in urine of smokers increased as the nominal tar level of
the cigarettes fell. Thus, not only was there no evidence of
reduced exposure per cigarette, but per cigarette exposure may
actually be higher with low-yield compared to higher yield
cigarettes.
Our ﬁndings indicate that the health claims associated with
the marketing of Chinese low-tar cigarettes are misleading to the
public. Smokers of low-yield cigarettes smoked fewer cigarettes
daily compared with regular smokers, even though smokers of
low-yield cigarettes reported increased daily consumption after
switching from regular to low-yield cigarettes. This result
suggests that these ‘switchers’ may tend to be more health
conscious and may have been smoking fewer cigarettes per day
than other smokers even before switching to low-tar cigarettes.
Health concern is one of the most often cited reasons for
switching to cigarettes with lower yields. Despite this lower
reported consumption, however, levels of nicotine metabolites
and carcinogens in the urine of people smoking low-yield ciga-
rettes were not lower than in people smoking regular cigarettes.
This result suggests that smokers of low-yield cigarettes have
compensated for lower nominal nicotine yields by smoking
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Figure 3 There is no signiﬁcant correlation between the levels of
cotinine (rs¼0.012, p¼0.782) or trans-39-hydroxycotinine (rs¼0.001,
p¼0.974) and the nominal tar yield of the main current brand.
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Research paperlow-yield cigarettes more intensively than smokers of regular
cigarettes.
1 2
Since cigarette offering is a common social etiquette in China,
smokers may smoke several brands of cigarettes at the same
time. Fortunately, all the smokers who smoked regular (15 mg
tar) cigarettes only smoked 15 mg tar cigarettes, even when they
smoked several different brands. The same situation held for
people smoking <10 mg tar cigarettes, all of whom smoked
8 mg tar cigarettes. For the 10e13 mg tar smokers, however,
there was some variation in the levels of tar among the several
brands that some of the people smoked, but all these brands fell
in the 10e13 mg tar range. Our analysis of the relationship of
nicotine metabolites and carcinogens with nominal tar levels
was based on the tar level for the most-smoked brand among
these people.
To examine the effect of brand mixing among the 10e13 mg
tar smokers on the relationship between urine metabolites and
tar yields, we tested indicators of nicotine intake and carcino-
genic indicators (total PAHs, total NNAL), as well as the per
cigarette levels of the four indicators, across the three tar levels
(10 mg, 12 mg and 13 mg) and found no signiﬁcant correlations
between exposure and yield among these subgroups. The effect
of brand mixing among the 10e13 mg tar smokers on the rela-
tionship between levels of urine metabolites and tar yields
among the entire sample (ﬁgures 3 and 4) should be minimal.
Our study supports the ﬁndings of previous studies that the
cigarette consumption adjusted cotinine level was not lower
among low-tar cigarette smokers than regular cigarette
smokers.
16 17
Our study is the ﬁrst to evaluate the safety claims of Chinese
low-tar cigarettes through direct measurement of biomarkers of
carcinogen exposure from tobacco smoke. There was no evidence
of reduced exposure to tobacco smoke toxins and therefore it is
unlikely that there would be any reduction in harm from
smoking low-tar cigarettes. The results of our study support the
evidence from other countries that low-tar cigarettes are not ‘less
harmful’ alternatives to regular cigarettes. The WHO Frame-
work Convention on Tobacco Control (FCTC) requires that
parties enact legislation ending the use of terms such as ‘low-
tar’, ‘light’, ‘ultra-light’ and ‘mild’ on cigarette packs because of
their false health implications (Article 11.1).
11 China ratiﬁed the
FCTC in 2005, but, as of April 2010 such terms still commonly
appeared on many cigarette packs in China. Such promotion
activity of CNTC is clearly a violation of the FCTC.
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